top of page
  • bluesky_media_kit_logo_transparent_3
  • Instagram
  • Twitter

Out of the Shadows: The Changing Story of Oropouche

Writer: Heather McSharry, PhD
Heather McSharry, PhD
1 hour ago
27 min read

Summary

For decades, Oropouche virus was best known for causing outbreaks of a dengue-like febrile illness in parts of Central and South America. But since late 2023, a dramatic increase in infections, geographic expansion, and reports of serious complications have brought this long-neglected virus into the spotlight.

In this episode, we explore the changing story of Oropouche, from its discovery in Trinidad in 1955 to the recent outbreaks that have challenged scientists' understanding of its transmission and disease potential. We examine the role of biting midges, the ecological conditions that influence where outbreaks occur, and how genetic reassortment may have shaped contemporary viral lineages.

We also take a closer look at emerging evidence linking Oropouche infection during pregnancy with fetal loss, maternal hemorrhage, and neurological abnormalities in infants, along with laboratory studies investigating how the virus infects placental and developing neural tissues.

Has Oropouche evolved into a more dangerous virus? Are changing environments creating new opportunities for transmission? Or are improved surveillance and research finally revealing risks that were present all along? The answer may involve all three.

Listen here or scroll down to read full episode.



Full Episode

For decades, Oropouche fever was generally considered an acute, self-limiting illness. It could make people very sick, sometimes for weeks, but most recognized infections weren't associated with severe complications.

Then, beginning in late 2023, Oropouche infections surged in Brazil, and the virus began appearing in places where it hadn't previously been reported.

As the outbreaks grew, researchers began documenting serious complications, including the first confirmed deaths attributed to Oropouche and evidence that infection during pregnancy could sometimes affect the developing fetus.

Oropouche has been causing outbreaks in parts of Central and South America for decades. Yet the recent surge has brought some unexpected developments. Researchers have identified a reassortant viral lineage and observed the virus spreading into new geographic areas.

These findings raise difficult questions: Why the sudden surge, geographic expansion, and recognition of severe disease? Did the virus change in ways that made it easier to spread or more likely to cause serious illness? Did changing environmental conditions bring more people into contact with the insects that transmit it? Has the virus become more dangerous, or are scientists finally recognizing complications that went undetected during earlier outbreaks?

The answer may be a combination of those possibilities.

This is Out of the Shadows: The Changing Story of Oropouche.

Meet Oropouche: A virus with a long history

The story of Oropouche virus begins in September 1955, on the island of Trinidad.

A 24-year-old forest worker from a community called Vega de Oropouche developed a fever, backache, and cough. His illness lasted about three days before resolving on its own. But when researchers at the Trinidad Regional Virus Laboratory examined a blood sample from the man, they isolated a virus that hadn't been identified before.

They named it Oropouche, after the community where the patient lived, near the Oropouche River.

Over the following decades, Oropouche would become associated with outbreaks of febrile illness across parts of Central and South America, particularly in Brazil's Amazon region.

Oropouche belongs to a group of viruses called orthobunyaviruses, in the family Peribunyaviridae. It's an enveloped RNA virus with a genome divided into three segments. We'll come back to those segments later because they may help explain some of the changes researchers have observed in the virus during the recent outbreaks.

For now, though, I want to focus on how Oropouche gets from one host to another.

You might recall that an arbovirus is a virus transmitted by an arthropod, such as a mosquito, tick, or biting fly. Dengue, Zika, chikungunya, yellow fever, and West Nile are all examples. But while we often associate arboviruses with mosquitoes, the primary vector responsible for Oropouche outbreaks is a much smaller insect called Culicoides paraensis.

It's a biting midge. You may know these guys as no-see-ums.

And if you've ever encountered biting midges, you probably remember them, even if you never actually saw what was biting you. They're tiny flies, often just a couple of millimeters long, and the females take blood meals to support egg production. Like mosquitoes, they can acquire a virus from an infected host and potentially transmit it during a later blood meal, provided the virus can successfully infect and replicate inside the insect.

Certain mosquitoes have also been implicated in transmission of Oropouche, but their precise roles vary by species and ecological setting.

Scientists believe Oropouche circulates through at least two interconnected transmission cycles.

One is called the sylvatic cycle, which is a term for transmission involving wildlife and arthropods in forested environments. Oropouche virus has been found in animals including three-toed sloths, and there is evidence of exposure in some nonhuman primates and birds. But researchers still haven't definitively established which animals maintain the virus in nature or which insect species are most important for transmitting it among those animals.

The second is the urban epidemic cycle, in which people become important hosts for the virus. If you've listened to some of our earlier episodes on mosquito-borne viruses, you might recognize these two transmission cycles. We've talked about sylvatic and urban transmission before, particularly with viruses like chikungunya. The same general principles apply here, even though we're talking about biting midges not mosquitoes.

So for the Oropouche urban cycle, the proposed pathway is that a person becomes infected in a forested environment, then travels into a community where competent biting midges are present. If those midges feed on the person while enough infectious virus is circulating in their blood, they may become infected themselves. After the virus has replicated and reached their salivary glands, the midges can transmit it to other people.

That creates the possibility of sustained transmission among people and insects, without requiring repeated introductions from infected wildlife.

And this brings us to something kinda interesting about Oropouche. Although it shares some of the same transmission patterns as mosquito-borne viruses like dengue, Zika, and chikungunya, where people are most likely to become infected can be pretty different.

In a study published in Nature Health in March 2026, researchers from Cornell University, the University of Kentucky, and collaborating institutions in Brazil analyzed more than a decade of Oropouche surveillance data collected by Brazil's Ministry of Health, from 2014 through 2025. The dataset included 30,086 laboratory-confirmed cases across 894 municipalities, spanning all 26 Brazilian states and the Federal District.

They found that, over that period, the cumulative reported incidence of Oropouche fever in rural municipalities was 11.3 times higher than in urban municipalities.

The researchers also compared the geographic distribution of Oropouche cases with existing surveillance data for dengue, chikungunya, and Zika. And they found almost the opposite pattern for those three mosquito-borne viruses, with substantially more reported cases in urban areas than in rural ones.

So even though these viruses can follow similar transmission cycles, the particular insects involved, the environments they inhabit, and the opportunities they have to encounter people can produce very different patterns of disease.

Now, that doesn't mean Oropouche is exclusively a rural disease. We know it can cause large urban outbreaks. And because the researchers were working with laboratory-confirmed cases, differences in surveillance and access to testing may have influenced the patterns they found.

But they were really trying to figure out what makes a community vulnerable to an outbreak in the first place. After all, introducing a virus into a community doesn't guarantee that an outbreak will follow. The virus needs opportunities to spread. For an insect-borne virus like Oropouche, that means suitable vectors, susceptible hosts, and environmental conditions that allow transmission to continue.

The researchers combined case reports with information about climate, land use, and population characteristics to estimate the probability that an introduction of Oropouche would lead to an outbreak in each Brazilian municipality.

And their maps identified communities with a relatively high predicted risk of an outbreak, even though they hadn't yet reported an introduction of the virus. Public health officials could actually use that information to prioritize those communities for surveillance, diagnostic testing, and vector control before an outbreak begins. Whether they did is a question I don't have an answer to.

Of course, these are statistical predictions, not guarantees. But the study illustrates something fundamental about infectious disease ecology. Where a virus can survive, where people encounter it, and where it can establish sustained transmission might be different places.

And that brings us back to the recent expansion of Oropouche. What changed in the environments where the virus was circulating? Did the opportunities for transmission change? Or had some communities been vulnerable for years, with infections going unrecognized?

We'll return to those questions when we examine the outbreaks that began in late 2023.

But first, we need to talk about what happens when Oropouche infects a person. Because for decades, the disease it caused was considered relatively predictable. And some of the recent findings are forcing researchers to reconsider that picture.

A familiar illness, an expanding outbreak

For most people who develop symptoms after an Oropouche infection, the illness begins fairly abruptly. One day they may feel fine, and the next they're dealing with fever, a headache, muscle and joint pain, and sometimes chills, nausea, vomiting, or a rash.

If that sounds familiar, there's a good reason. Those symptoms overlap with several other infections common in tropical regions, including dengue and chikungunya. And in places where those viruses circulate, a patient with fever, headache, and muscle pain isn't necessarily going to be tested for Oropouche.

The incubation period, which is the time between infection and the appearance of symptoms, is generally about three to ten days for this virus. Most symptomatic infections resolve within a week, although some people experience fatigue or weakness that lasts longer. And Oropouche has another characteristic that can complicate the clinical picture: symptoms sometimes return after the patient initially seems to have recovered.

That recurrence has been described in Oropouche outbreaks for decades. A person may feel better for several days, only to develop another episode of fever, headache, or other symptoms. The biological explanation isn't entirely clear. And importantly, recurrent symptoms don't necessarily mean that the person has been infected again or that the virus is still actively replicating.

Historically, Oropouche fever was generally mild, but neurological involvement has also been documented, including meningitis and, less commonly, encephalitis.

Meningitis is inflammation of the membranes surrounding the brain and spinal cord. Encephalitis involves inflammation of the brain tissue itself. Both can have infectious and noninfectious causes, and distinguishing them can be difficult.

For Oropouche, researchers have detected viral genetic material in cerebrospinal fluid from some patients with neurological disease. That supports the ability of the virus to involve the central nervous system, although the mechanisms responsible for neurological injury are still being investigated.

Then, in 2024, Brazil reported the first deaths formally attributed to Oropouche infection. These included previously healthy young adults who developed severe illness.

That was a significant development for a virus generally described as causing a nonfatal febrile disease. But it also raised an important question: Were severe and fatal infections becoming more common, or were investigators finally recognizing outcomes that had previously gone undetected?

We don't yet have enough information to answer that confidently.

Part of the problem is that Oropouche has historically received far less diagnostic and surveillance attention than dengue, chikungunya, or Zika.

When someone develops a fever in a region where several arboviruses circulate, clinicians generally begin with the infections they're most likely to encounter and for which diagnostic testing is available. If dengue testing is negative, that doesn't automatically mean the patient will be tested for Oropouche. Depending on the setting, they may never receive a specific viral diagnosis.

And even when Oropouche testing is available, the timing is important.

During the early phase of infection, laboratories can use molecular methods such as reverse-transcription polymerase chain reaction, or RT-PCR, to detect viral RNA in a patient's blood. But the period during which viral RNA can reliably be detected is limited. Later in the illness, antibody testing may be more useful, although interpretation can be complicated by the availability and specificity of different assays.

That means surveillance systems relying heavily on laboratory-confirmed cases may miss infections, especially when people have mild symptoms, don't seek medical care, or aren't tested during the appropriate window.

Researchers have suspected for years that the true burden of Oropouche infection was considerably greater than official case counts suggested.

And the recent outbreaks have provided some evidence supporting that concern.

In a study published in Nature Medicine in March 2026, researchers investigated Oropouche transmission in Manaus, a major city in Brazil's Amazon region. They combined serological evidence of previous infection with genomic and epidemiological analyses to reconstruct how the virus had circulated.

Serology allows researchers to look for evidence of past exposure by measuring antibodies. It can therefore reveal infections that weren't necessarily recognized or reported when they occurred.

The researchers found that the estimated proportion of people with evidence of previous Oropouche infection increased from 11.4 percent in November 2023 to 25.7 percent in November 2024.

That's a substantial increase over a single year and it suggests that many infections may have gone unrecognized by routine surveillance. Serological studies have limitations, including questions about assay specificity and how representative the sampled population is. But they provide a way to investigate transmission that doesn't depend entirely on whether someone sought medical care and received a diagnosis.

Now, Oropouche outbreaks in Brazil weren't new. The virus had caused repeated epidemics in the Amazon basin since the 1960s, including large outbreaks involving thousands of reported cases.

What changed in late 2023 and 2024 was the scale and geographic distribution of transmission.

Cases increased sharply in parts of northern Brazil, and the virus was subsequently detected across a much wider area of the country. Some affected communities had little or no previously documented Oropouche transmission.

The expansion also extended beyond Brazil.

In 2024, Cuba reported its first recognized Oropouche outbreak. Other countries in the Americas identified infections, and travel-associated cases were detected in North America and Europe.

Now, as we've talked about in other episodes, finding a virus in a traveler doesn't mean that the virus has established local transmission in the country where that traveler was diagnosed. It means the person acquired the infection elsewhere and carried it across a geographic boundary.

For sustained local transmission to occur, the virus needs suitable vectors, opportunities for those vectors to become infected, and enough subsequent transmission to maintain the cycle.

And that distinction becomes useful when we look at what researchers learned from the Cuban outbreak.

In a genomic study published in Nature Medicine in July 2026, investigators analyzed viral sequences to reconstruct how Oropouche entered and spread through Cuba. Their findings suggest that the virus may have been introduced around February 2024, approximately three months before the first infections were officially recognized.

In other words, the virus may already have been circulating before surveillance identified the outbreak.

But once researchers have viral genome sequences from different patients, they can begin reconstructing relationships among infections, and estimate when lineages diverged and how the virus may have moved through populations.

Those estimates depend on sampling and evolutionary assumptions, so they aren't exact dates. Still, they can reveal transmission histories that case reports alone cannot establish.

And by 2026, researchers had assembled a much more detailed picture of Oropouche's recent expansion.

The ecological study we discussed earlier found laboratory-confirmed infections across all 26 Brazilian states and the Federal District between 2014 and 2025. It also identified substantial geographic differences in outbreak risk, including municipalities where environmental and demographic conditions suggested that an introduction could lead to transmission even though no introduction had yet been reported.

Taken together, these studies suggest that the expansion of Oropouche involved more than a sudden increase in reported case numbers. The virus was reaching new populations, circulating in places where it hadn't previously been recognized, and encountering ecological conditions that could support further transmission.

But the environmental explanation may be only part of the story.

Because when scientists began sequencing viruses associated with the recent outbreaks, they found that a reassortant viral lineage was circulating.

And to understand why that caught researchers' attention, we need to look more closely at the Oropouche genome.

A virus that can shuffle its genome

Earlier, I mentioned that Oropouche has a genome divided into three segments. Those segments are called L, M, and S, for large, medium, and small.

Like all viruses, Oropouche depends on the cells it infects to reproduce. But its genome has an unusual feature that gives it opportunities for genetic change beyond the mutations that accumulate as viral genomes are copied.

Oropouche is a negative-sense RNA virus. That means its genomic RNA can't be read directly by the host cell's ribosomes to make viral proteins. The virus has to bring its own RNA-dependent RNA polymerase into the cell, where that enzyme produces messenger RNA that the cell's machinery can translate.

The L segment encodes that polymerase. The M segment encodes a precursor that is processed into proteins including the glycoproteins on the virus's surface, which help it enter cells. And the S segment encodes the nucleocapsid protein, which associates with the viral RNA, along with a nonstructural protein called NSs that can interfere with the host's antiviral responses.

Each segment contributes something different to the virus's ability to infect cells, reproduce, and interact with its host.

And because those segments are separate pieces of RNA, there's an additional way for the virus to generate genetic diversity.

It's called reassortment.

Imagine that a single cell becomes infected with two genetically different Oropouche viruses. Both viruses begin replicating their genomes, producing copies of their L, M, and S segments.

When new virus particles assemble, some may package a mixture of segments derived from the two parental viruses.

A progeny virus might inherit its L and S segments from one parental lineage and its M segment from the other.

That process is reassortment.

It's different from an ordinary mutation, where changes occur within a genome segment as the viral RNA is copied. Reassortment can exchange an entire segment, bringing together combinations of viral genes that previously existed in different lineages.

Influenza viruses are another familiar example of viruses with segmented genomes that can reassort, although influenza has eight genome segments rather than three.

Now, reassortment doesn't automatically make a virus more dangerous. Many possible combinations may be poorly suited to replication or may never establish themselves in a population. The different viral proteins still have to work together, and the resulting virus has to be capable of completing its replication cycle.

But some combinations can alter biological properties, including how efficiently a virus replicates, how it interacts with host defenses, or how well it infects particular hosts or vectors.

And during the recent Oropouche outbreaks, researchers identified a reassortant lineage that appeared to have been circulating for considerably longer than the outbreaks themselves.

In a study published in Nature Medicine in September 2024, investigators analyzed 382 Oropouche genomes collected from human infections in the western Brazilian Amazon between August 2022 and February 2024.

They found that the lineage associated with the outbreak carried an M segment related to viruses previously detected in the eastern Amazon, while its L and S segments were related to viruses circulating in parts of the western Amazon and neighboring countries, including Peru, Colombia, and Ecuador.

That combination provided evidence of reassortment between distinct Oropouche lineages.

But the timing was particularly interesting.

Based on the genetic relationships among the sampled viruses, the researchers estimated that the reassortant lineage probably emerged in Amazonas state sometime between 2010 and 2014.

That's roughly a decade before the large outbreaks that brought it to widespread attention.

The lineage appears to have circulated and dispersed over several years before becoming associated with the dramatic increase in recognized infections during 2023 and 2024.

So the appearance of a reassortant lineage in an outbreak doesn't necessarily mean that reassortment happened immediately before the outbreak began.

And there's another question we need to consider: Did this particular combination of genome segments give the virus some biological advantage?

Researchers have begun investigating that possibility.

In a 2024 study examining the reemergence of Oropouche in Brazil, investigators compared a contemporary epidemic strain with a historical reference strain in laboratory experiments.

They found that the contemporary strain produced a lot higher viral titers in mammalian cell cultures. They also observed differences in plaque formation, which is one way researchers assess how viruses spread through susceptible cells in culture.

In addition, serum collected from people who had previously been infected with Oropouche showed substantially reduced neutralizing activity against the contemporary reassortant strain compared with the historical strain.

Neutralizing antibodies are antibodies that can interfere with a virus's ability to infect cells. So reduced neutralization in a laboratory assay raises the possibility that prior immunity may be less effective against some contemporary strains.

Researchers have also investigated whether contemporary strains differ in their ability to cause disease.

In a study published in May 2026, scientists compared two Oropouche isolates collected during the 2024 outbreaks with a historical reference strain in mice.

The contemporary isolates produced higher levels of virus in the blood, more rapid disease progression, and greater mortality. The researchers also detected increased viral burdens in several organs, including the brain.

That last finding is especially interesting given the neurological complications reported in some human infections.

But the experiment used AG129 mice, which lack functional receptors for type I and type II interferons. Interferons are important signaling proteins that help coordinate the body's early antiviral defenses. Without those responses, mice can be unusually susceptible to viral infections.

That makes the model useful for studying certain aspects of Oropouche pathogenesis, but it also means we have to be cautious about extrapolating the results to people with intact immune systems.

The findings provide experimental evidence that contemporary isolates can behave differently from a historical strain under the conditions tested. But the isolates differ genetically beyond just which genome segments they inherited. So the experiments can't tell us whether reassortment itself caused the observed differences, or whether other genetic changes contributed. And they don't establish that contemporary Oropouche strains cause more severe disease in humans.

Taken together, these studies suggest that contemporary Oropouche strains can behave differently from historical ones. But whether those differences contributed to the recent outbreaks, and how much ecological conditions played a role, remains uncertain.

And there's another possibility to consider. Some of the changes we're seeing may reflect what researchers are now looking for, rather than entirely new properties of the virus.

That's especially relevant to one of the most concerning developments during the recent outbreaks: the recognition of complications during pregnancy.

Oropouche and pregnancy: What the evidence tells us

In 2024, Brazilian health authorities began investigating reports of fetal deaths and congenital abnormalities in pregnancies where the mother had been infected with Oropouche virus. Some of those investigations identified viral RNA in fetal or placental tissues, providing evidence that the virus could cross from an infected pregnant woman to her developing fetus.

This kind of transmission is called vertical transmission. The term describes the passage of an infection from a parent to their offspring, which can occur during pregnancy, delivery, or, for some infections, breastfeeding.

For Oropouche, the concern is mostly about transmission during pregnancy, when the virus may reach the placenta and potentially infect fetal tissues. And researchers are still determining how often infection during pregnancy leads to adverse outcomes, which tissues are most vulnerable, and what mechanisms might be responsible.

By 2025, researchers had published several investigations describing pregnancy outcomes among women infected with Oropouche.

One study from Espírito Santo, Brazil, followed 73 pregnancies, although only 15 had reached an outcome by the end of the study period. Among those, researchers documented one spontaneous abortion and one infant born with an abnormality involving the corpus callosum, the structure connecting the brain's two hemispheres. They also detected Oropouche viral RNA in placental samples from several pregnancies.

Another study examined six pregnancies with a range of outcomes, including fetal loss and apparently normal development. In some cases, investigators detected the virus in fetal tissues and documented serious neurological and other organ damage.

These were small observational investigations, so they couldn't establish how frequently complications occur or whether Oropouche caused every abnormality. But they provided evidence that the virus could reach fetal tissues and gave researchers a compelling reason to investigate how infection during pregnancy might affect development.

One of the questions investigators needed to answer was whether Oropouche could actually infect the placenta.

In May 2026, researchers published a study in Nature Communications examining how Oropouche interacts with placental tissue and whether contemporary viral strains differed from historical ones.

And they found that both historical and contemporary strains could infect placental tissue in the experimental models. That suggests the ability to infect the placenta isn't necessarily a new property of the lineage associated with the recent outbreaks.

It doesn't mean every strain poses the same risk during pregnancy, but it raises the possibility that some congenital risks existed before researchers began recognizing them.

Another important question is how the maternal immune response influences whether the virus reaches the fetus.

In a January 2026 study, researchers investigated the role of type I interferons, that part of the body's early antiviral defense I mentioned before, in pregnant mice.

They found that maternal interferon responses helped restrict viral replication and protect against fetal infection.

That suggests the mother's immune defenses may be one reason infection doesn't always lead to transmission across the placenta. But differences between mouse and human pregnancy mean these experiments can't tell us how frequently fetal infection occurs in people.

Researchers have also investigated what happens when Oropouche reaches developing nervous tissue.

In September 2026, a study using human brain organoids examined the effects of Oropouche infection on developing neural cells.

Organoids are really cool. They are three-dimensional structures grown from cells in the laboratory. Under the right conditions, those cells can organize into tissues that reproduce some features of developing human organs.

Brain organoids don't reproduce an entire human brain, but they allow researchers to study how developing human neural cells respond to infection.

The investigators found that Oropouche could infect those cells and cause damage in their experimental systems. That supports the biological plausibility of neurological injury during fetal development, although it doesn't tell us how often such complications occur in human pregnancies.

For that, we need clinical and epidemiological evidence.

In October 2026, researchers published a prospective cohort study in The Lancet Infectious Diseases examining pregnancy outcomes among women in Rio de Janeiro.

Unlike the earlier case reports and small clinical investigations, this study followed hundreds of pregnant women, including 130 with confirmed Oropouche infections.

The researchers found that women with confirmed infections had approximately three times the risk of fetal loss and maternal hemorrhage compared with women without infection. Those associations remained after adjusting for several potential confounding factors.

They also found an increased risk of adverse infant outcomes. Central nervous system abnormalities were documented in eight infants born to mothers with confirmed infections, compared with none in the uninfected group.

These findings provide stronger epidemiological evidence than individual case reports, but the study is still observational. And while the associations are concerning, they don't establish that Oropouche caused every adverse outcome observed, or tell us how frequently complications will occur across different populations and stages of pregnancy.

And I should clarify that the ability of a virus to cross the placenta, the likelihood that it will infect fetal tissues, and the probability that an infected fetus will develop abnormalities are three different things.

A pregnant woman can become infected without the virus reaching the fetus. A fetus may become infected without developing detectable abnormalities. And the consequences of fetal infection may depend on when during development it occurs, which tissues are infected, and how the maternal and fetal immune responses interact with the virus.

Those distinctions are central to understanding congenital infections, and they're among the questions researchers are now trying to answer for Oropouche.

Together, these studies are changing how researchers understand Oropouche during pregnancy. But they also complicate the idea that the virus suddenly acquired the ability to cause serious complications.

Historical strains can infect placental tissue, and earlier outbreaks received far less attention than the recent ones. Some risks may have existed for decades without being recognized.

Whether contemporary strains have also acquired properties that affect those risks remains an open question.

Where Oropouche goes from here

So where does all of this leave us?

Oropouche has been circulating in parts of the Americas for decades, but the outbreaks beginning in late 2023 revealed how much we still don't understand about its transmission, geographic distribution, and the disease it causes.

And one question that naturally follows from its recent expansion is whether the virus could establish sustained transmission in places where it hasn't circulated before.

That includes the United States.

Now, the fact that Oropouche has been detected in travelers returning to the United States doesn't mean the virus is circulating locally. Those infections were acquired elsewhere, in places where Oropouche transmission was already occurring.

According to CDC surveillance data updated in November 2026, the United States reported 108 travel-associated Oropouche cases in 2024 and two in 2025. No cases had been reported in 2026 as of that update, and no locally acquired infections had been identified. But could local transmission occur?

The principal recognized vector, *Culicoides paraensis*, occurs in parts of North America, including the southeastern United States. But for local transmission to occur, biting midges must be capable of acquiring and transmitting the virus, and their abundance, feeding behavior, and environmental conditions must allow transmission to continue.

That's an important distinction between vector competence—the insect's biological ability to transmit a pathogen—and its actual contribution to transmission in nature.

And because Oropouche relies on different vectors than dengue or Zika, we shouldn't assume it will follow the same geographic patterns.

The distinction between introduction and sustained transmission is useful when considering the virus's future.

An infected traveler could arrive in an area where biting midges are present, but that alone wouldn't establish a transmission cycle. The relevant insects would need to feed on that person while infectious virus was present, become infected themselves, and subsequently transmit the virus to susceptible hosts.

And even then, a small number of infections might not develop into a sustained outbreak.

The same questions apply to regions of Central and South America where Oropouche hasn't historically been recognized.

As the virus reaches new communities, researchers need to determine which environments can support transmission, which vectors are involved, and how much circulation may already be occurring without being detected.

And in places where Oropouche hasn't historically been recognized, limited diagnostic testing could allow transmission to go undetected.

As we've seen, distinguishing genuinely new geographic expansion from previously unrecognized circulation is one of the major challenges facing researchers.

And that brings us to another challenge: prevention.

There is currently no licensed vaccine against Oropouche virus and no antiviral treatment specifically approved for the infection.

For most patients, care focuses on managing symptoms and monitoring for complications. Preventing infection depends largely on reducing exposure to biting midges in areas where transmission occurs.

That sounds straightforward, but biting midges present some practical difficulties.

They're extremely small, and some can pass through the mesh of ordinary window screens or mosquito nets. Finer mesh can help exclude them, although it may also reduce airflow. Insect repellents, protective clothing, and appropriately screened indoor spaces can reduce exposure.

At the community level, vector control requires understanding where the relevant midge species breed and how they interact with people.

And those details can differ from the strategies used against mosquitoes.

For example, eliminating containers of standing water is an important part of controlling Aedes aegypti, the mosquito responsible for much dengue, Zika, and chikungunya transmission. But biting midges may develop in moist organic material and other habitats that require different control approaches.

That's another reason the ecological research matters. Public health officials need to understand the actual transmission system they're trying to interrupt.

Despite the progress made over the past few years, important questions remain about Oropouche's natural transmission cycle, the role of genetic changes in its recent expansion, and the risks of infection during pregnancy.

Answering those questions will require continued surveillance, laboratory research, and careful follow-up of affected patients.

But the evidence we have now points to something more complicated than a virus that suddenly changed.

Oropouche has certainly evolved genetically, and changing ecological conditions may have created new opportunities for transmission. But our ability to detect the virus and recognize its complications has also improved.

We still don't know how much each of those factors contributed to what we've observed.

And I think that's what makes the Oropouche story so interesting.

Scientists have known about this virus since 1955. They've documented outbreaks for decades. But knowing that a virus exists, and even knowing that it causes disease, doesn't mean we understand its ecology, its evolution, or the full range of outcomes it can produce.

Oropouche has been part of the infectious disease landscape for more than 70 years.

We're still learning what that means.


Gypsy poking her head out from under my desk to say hi while I recorded an episode.
Gypsy poking her head out from under my desk to say hi while I recorded an episode.

Thanks for listening. For those who made it this far, I wanted to share something

personal. Last week, I lost my sweet girl, Gypsy. If you've listened to some of my other episodes, you've probably heard me talk about her, and you may have even heard her walking around or barking in the background. She was my little companion through so much of the work that goes into making this podcast, and I miss her so very much. .

I just wanted to take a moment to remember her here, because in her own way, she was part of this show.


And for anyone with their own fur baby of any stripe...give em an extra hug for me.












Annotated Citations

Each citation is annotated to explain how the source connects to the episode and to help listeners who want to explore the science in greater depth.

Accessing the literature: Whenever possible, I've linked directly to free full-text articles and books that are legally available online. For subscription-only journal articles, many researchers are happy to share a personal copy of their work if you contact the corresponding author. For books, I've included links to free online lending copies or library catalogs when available.


Ecology, transmission & geographic expansion

  • Hua X, et al. 2026. Ecological and demographic drivers of Oropouche virus transmission. Nature Health.

    → An analysis of more than a decade of Brazilian surveillance data, examining where Oropouche outbreaks occur and which environmental and demographic conditions may favor transmission. The researchers found substantially higher reported incidence in rural than urban municipalities and identified communities where future introductions could potentially lead to outbreaks. The study illustrates why the geographic distribution of Oropouche differs from that of more familiar mosquito-borne viruses.

    🔒 Subscription required: https://www.nature.com/articles/s44360-026-00065-6

    But scroll down in the article at this link for a direct link to the PDF: https://jornal.unicamp.br/en/noticias/2026/03/24/novo-estudo-indica-avanco-do-virus-oropouche-em-todas-as-regioes-do-brasil/

  • Manuli ER, et al. 2026. Transmission dynamics of Oropouche virus in Latin America and the Caribbean. Nature Medicine.

    → A revealing study of how much Oropouche transmission may have gone unrecognized. In Manaus, Brazil, the estimated proportion of people with evidence of previous infection increased from 11.4% in November 2023 to 25.7% in November 2024. These findings help explain why laboratory-confirmed case counts can underestimate how widely a virus has circulated.

    🔒 Subscription required: https://www.nature.com/articles/s41591-026-04221-z

    But scroll down in the article at this link for a direct link to the PDF (same link as above. Both papers are linked if you scroll down): https://jornal.unicamp.br/en/noticias/2026/03/24/novo-estudo-indica-avanco-do-virus-oropouche-em-todas-as-regioes-do-brasil/

  • Gravier R, et al. 2026. Spatiotemporal diffusion of the 2024 Oropouche outbreak in Cuba. Nature Medicine.

    → Using viral genome sequences, researchers reconstructed the introduction and spread of Oropouche in Cuba. Their analyses suggest the virus arrived around February 2024, approximately three months before the first infections were officially recognized. It's a useful example of how genomic epidemiology can reveal transmission that occurred before an outbreak was detected.

    🆓 Open access: https://www.nature.com/articles/s41591-026-04411-9

Viral evolution, reassortment & disease severity

  • Naveca FG, et al. 2024. Human outbreaks of a novel reassortant Oropouche virus in the Brazilian Amazon region. Nature Medicine.

    → One of the central studies behind this episode. Researchers analyzed 382 viral genomes and identified a reassortant lineage associated with the recent epidemic. Their findings suggest this lineage emerged around 2010–2014, long before the large outbreaks of 2023–2024. The study helps explain how Oropouche has evolved, while also showing why the discovery of a new viral lineage doesn't necessarily mean it emerged immediately before an outbreak.

    🔒 Subscription required: https://www.nature.com/articles/s41591-024-03300-3

    But the authors have made a free PDF available at ResearchGate:

    https://www.researchgate.net/publication/384112805_Human_outbreaks_of_a_novel_reassortant_Oropouche_virus_in_the_Brazilian_Amazon_region

  • Scachetti GC, et al. 2025. Reemergence of Oropouche virus between 2023 and 2024 in Brazil. 2024. Lancet Infect Dis.

    → Researchers compared a contemporary epidemic strain with a historical Oropouche strain in laboratory experiments. They observed differences in viral replication and reduced neutralization of the contemporary strain by antibodies from previously infected individuals. These results raise important questions about how the virus may have changed, although laboratory findings alone cannot establish whether contemporary strains spread more efficiently or cause more severe disease in people.

    🆓 Open access: https://pmc.ncbi.nlm.nih.gov/articles/PMC11779697/

  • Santos ECN, et al. 2026. Enhanced virulence and neuroinvasion of contemporary Oropouche virus strains in the AG129 mouse model. Frontiers in Microbiology.

    → A comparison of contemporary and historical Oropouche strains in mice. Contemporary isolates produced more severe disease, higher viral burdens, and greater mortality under the experimental conditions. Importantly, the researchers used mice lacking key interferon responses, making them unusually susceptible to infection. The results identify biological differences worth investigating, but they don't establish that contemporary strains are more dangerous to humans.

    🆓 Open access: https://pmc.ncbi.nlm.nih.gov/articles/PMC13226609/

Oropouche infection during pregnancy

  • Cola JP, et al. 2025. Maternal and Fetal Implications of Oropouche Fever, Espírito Santo State, Brazil, 2024. Emerging Infectious Diseases.

    → An early investigation of Oropouche infections during pregnancy, including placental testing and pregnancy outcomes. The findings helped raise concerns about possible vertical transmission and fetal complications. Because the number of completed pregnancies was small, the study could not determine how frequently these outcomes occur.

    🆓 Open access: https://pmc.ncbi.nlm.nih.gov/articles/PMC11950280/

  • Medeiros DBA, et al. 2025. Case Series of Adverse Pregnancy Outcomes Associated with Oropouche Virus Infection. Viruses.

    → A detailed investigation of pregnancies affected by Oropouche infection, including cases involving fetal loss and developmental abnormalities. Evidence of viral infection in fetal tissues strengthened concerns about transmission during pregnancy. As a small case series, however, the study cannot establish the overall risk of complications or show that every observed abnormality was caused by Oropouche.

    🆓 Open access: https://pmc.ncbi.nlm.nih.gov/articles/PMC12197463/

  • Megli CJ, et al. 2025. Oropouche virus infects human trophoblasts and placenta explants. Nature Communications.

    → Researchers used human placental cells and tissue to investigate whether Oropouche can infect the placenta, which normally helps protect the developing fetus from infection. Their findings provide experimental evidence of placental susceptibility and help explain a possible pathway for maternal-fetal transmission. This is an important biological piece of the emerging pregnancy evidence, although laboratory infection doesn't tell us how frequently transmission occurs in people.

    🆓 Open access: https://www.nature.com/articles/s41467-025-61138-w

  • Gunter KB, et al. 2026. Conserved pathogenesis of ancestral and contemporary Oropouche virus strains in a murine pregnancy model. Nature Communications.

    → Researchers compared an ancestral Oropouche strain with a contemporary outbreak-associated isolate using pregnant mice and human placental cell models. Both strains could infect placental tissue, demonstrating that placental susceptibility is not necessarily a newly acquired property of contemporary Oropouche viruses. Although the contemporary strain showed some differences in replication and placental infection frequency, the findings suggest that the potential for maternal-fetal transmission may have existed before the recent outbreaks brought congenital complications to researchers' attention.

    🆓 Open access: https://www.nature.com/articles/s41467-026-72711-2

  • Muraro SP, et al. 2026. Type I interferon controls vertical transmission and fetoplacental infection of Oropouche virus. iScience.

    → An experimental investigation of how the mother's antiviral immune response influences infection during pregnancy. The findings suggest that type I interferon signaling helps restrict viral replication and protect against fetal infection. This offers a possible explanation for why maternal infection does not always lead to transmission across the placenta, while also highlighting the limitations of translating mouse experiments directly to human pregnancy.

    🆓 Open access: https://pmc.ncbi.nlm.nih.gov/articles/PMC12918160/

  • Bannerman C, et al. 2026. Oropouche virus disrupts neurodevelopment and exhibits congenital infection potential. Nature Communications.

    → Researchers investigated how Oropouche infection affects developing neural tissue, including human brain organoid models. Their experiments showed that the virus can infect developing neural cells and cause cellular damage. These findings provide biological support for concerns about fetal neurological injury.

    🆓 Open access: https://www.nature.com/articles/s41467-026-77859-5

  • Brasil P, et al. 2026. Oropouche virus infection in pregnant women in Rio de Janeiro, Brazil: a prospective cohort study. The Lancet Infectious Diseases.

    → One of the most important clinical studies discussed in this episode. Researchers enrolled 544 pregnant women, including 130 with confirmed Oropouche infections, and compared maternal and infant outcomes. Women with confirmed infections had approximately three times the adjusted risk of fetal loss and maternal hemorrhage compared with uninfected women. Adverse infant outcomes were also more frequent, and central nervous system abnormalities were documented in eight infants of infected mothers compared with none in the uninfected group. This prospective study provides stronger epidemiological evidence than earlier case reports, although its observational design cannot establish that every adverse outcome was caused by Oropouche.

    🔒 Subscription required: https://pubmed.ncbi.nlm.nih.gov/42896562/

    You can request a copy of the PDF from the authors on ResearchGate:

    https://www.researchgate.net/publication/416341963_Oropouche_virus_infection_in_pregnant_women_in_Rio_de_Janeiro_Brazil_a_prospective_cohort_study

Symptoms, clinical disease & public health

  • Travassos da Rosa JF, et al. 2017. Oropouche virus: clinical, epidemiological, and molecular aspects of a neglected orthobunyavirus. American Journal of Tropical Medicine and Hygiene.

    → A comprehensive review of Oropouche virus research, covering its history, transmission ecology, clinical manifestations, and molecular biology. The authors describe the virus's sylvatic and urban transmission cycles, the roles of biting midges and other potential vectors, and evidence of infection in wildlife. The review also examines historical outbreaks, neurological complications, and the virus's segmented genome. It provides important background for understanding what scientists knew about Oropouche before the recent outbreaks and highlights longstanding gaps in knowledge about its natural transmission cycle.

    🆓 Open access: https://pmc.ncbi.nlm.nih.gov/articles/PMC5417190/

  • Anderson CR, et al. 1961. Oropouche virus: a new human disease agent from Trinidad, West Indies. American Journal of Tropical Medicine and Hygiene.

    → The original scientific report describing the isolation and characterization of Oropouche virus from a patient with a febrile illness in Trinidad in 1955. The researchers named the virus after the region where the infection was identified and investigated its relationship to other known viruses. They also detected evidence of previous exposure in forest workers and nonhuman primates.

    🔒 Subscription required: https://www.ajtmh.org/view/journals/tpmd/10/4/article-p574.xml

  • Giri M, et al. 2025. Clinical manifestations of Oropouche virus infection: A systematic review and meta-analysis. Medicine International.

    → A synthesis of 28 studies involving more than 4,000 patients, examining the symptoms associated with Oropouche infection. The review provides a broader picture of the disease beyond individual outbreaks, including fever, headache, muscle and joint pain, fatigue, and gastrointestinal symptoms. Differences among the included studies are an important reminder that symptom frequencies can vary across populations and outbreaks.

    🆓 Open access: https://pmc.ncbi.nlm.nih.gov/articles/PMC12416135/

  • World Health Organization. Oropouche virus disease.

    → A reliable overview of Oropouche, including its transmission, symptoms, geographic distribution, and public-health significance. This is a useful starting point for readers who want the essential background without diving into the primary research.

    🌐 Free online resource: https://www.who.int/news-room/fact-sheets/detail/oropouche-virus-disease

  • Centers for Disease Control and Prevention. Oropouche: Prevention.

    → Practical guidance for reducing exposure to the biting midges that transmit Oropouche. Because these insects are much smaller than mosquitoes, some familiar mosquito-control strategies may be insufficient. The guidance explains protective measures for travelers and people living in affected areas.

    🌐 Free online resource: https://www.cdc.gov/oropouche/prevention/index.html

  • Centers for Disease Control and Prevention. Oropouche in the United States.

    → CDC surveillance data on travel-associated Oropouche infections reported in the United States. These figures help distinguish infections acquired during travel from locally acquired transmission. The page is updated periodically, so readers should consult it for the most recent reported numbers.

    🌐 Free online resource: https://www.cdc.gov/oropouche/data-maps/current-year-data.html



Comments


IDSmallEmblem_edited.jpg

Infectious disease science, stories, and outbreaks.

Medical Disclaimer: Content on Infectious Dose is for general educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding personal medical decisions.

© 2025-2026 by Infectious Dose

bottom of page